Cargando…
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
Background: In adults aged ≥60 years, two doses of the herpes zoster subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01(B) Adjuvant System) elicited humoral and cell-mediated immune responses persisting for at least six years. We assessed immunogenicity nine years post...
Autores principales: | Schwarz, Tino F., Volpe, Stephanie, Catteau, Gregory, Chlibek, Roman, David, Marie Pierre, Richardus, Jan Hendrik, Lal, Himal, Oostvogels, Lidia, Pauksens, Karlis, Ravault, Stephanie, Rombo, Lars, Sonder, Gerard, Smetana, Jan, Heineman, Thomas, Bastidas, Adriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037441/ https://www.ncbi.nlm.nih.gov/pubmed/29461919 http://dx.doi.org/10.1080/21645515.2018.1442162 |
Ejemplares similares
-
Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults
por: Pauksens, Karlis, et al.
Publicado: (2017) -
2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
por: Bastidas, Adriana, et al.
Publicado: (2019) -
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020) -
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
por: Cunningham, Anthony L, et al.
Publicado: (2018) -
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
por: Rümke, Hans C, et al.
Publicado: (2013)